Cited by 262Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismCoenzyme Q10 studies and effects

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Effects of an Inhibitor of 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase on Serum Lipoproteins and Ubiquinone-10 Levels in Patients with Familial Hypercholesterolemia

Mabuchi, Hiroshi, Haba, Toshihiro, Tatami, Ryzo, Miyamoto, Susumu, Sakai, Yasuyuki, Wakasugi, Takanobu, Watanabe, Akira, Koizumi, Junji, Takeda, Ryoyu·1981·New England Journal of Medicine

DOI 10.1056/nejm198108273050902

Open this paper in CoChat — free account

Abstract

We studied the effects of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum levels of lipoproteins and ubiquinone-10-in seven heterozygous patients with familial hypercholesterolemia. ML-236B was given at doses of 30 to 60 mg per day for 24 weeks. Serum cholesterol decreased from 390 +/- 9 to 303 +/- 8 mg per deciliter (101 +/- 0.2 to 7.88 +/- 0.2 mmol per liter, mean +/- S.E.M.; p less than 0.001) and serum triglyceride decreased from 137 +/- 18 to 87 +/- 9 mg per deciliter (1.55 +/- 0.20 to 0.98 +/- 0.01 mmol per liter; p less than 0.05). Intermediate-density-lipoprotein (DL) cholesterol, IDL triglyceride, low-density-lipoprotein (LDL) cholesterol, and LDL triglyceride decreased significantly (p less than 0.01, P less than 0.001, and P less than 0.001, respectively). However, there were no significant changes in very-low-density-lipoprotein (VLDL) cholesterol and triglyceride or high-density-lipoprotein (HDL) cholesterol. Serum ubiquinone-10 levels did not change, and LDL levels of ubiquinone-10 decreased by 50 per cent, from 0.39 +/- 0.07 to 0.20 +/- 0.01 microgram per milliliter (P less than 0.05). No adverse effects were observed. We conclude that ML-236B is effective in lowering serum cholesterol without lowering serum ubiquinone-10 in heterozygous patients with familial hypercholesterolemia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm198108273050902

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Enzymatic determination of total serum cholesterol.
Allain, C. C., Poon, L. S., Chan, C. S. G., Richmond, W., & Fu, P. C. (1974) · Clinical Chemistry · doi:10.1093/clinchem/20.4.470 · Cited by 9,845
THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM
Havel, R. J., Eder, H. A., & Bragdon, J. H. (1955) · Journal of Clinical Investigation · doi:10.1172/jci103182 · Cited by 8,737
PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE
Miller, G. J., & Miller, N. E. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92376-4 · Cited by 2,621
The Low-Density Lipoprotein Pathway and its Relation to Atherosclerosis
Goldstein, L. J., & Brown, S. M. (1977) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.46.070177.004341 · Cited by 1,906
Clofibrate and Niacin in Coronary Heart Disease
Stamler, J. (1975) · JAMA · doi:10.1001/jama.1975.03240160024021 · Cited by 1,750
Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent.
Alberts, A. W., Chen, J., Kuron, G. W., Hunt, V. M., Huff, J. W., Hoffman, C., Rothrock, J. W., López, M., Joshua, H., Harris, E., et al. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.7.3957 · Cited by 1,630
Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth.
Brown, M. S., & Goldstein, J. L. (1980) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42221-7 · Cited by 1,210
A colorimetric method for estimating serum triglycerides
Fletcher, M. J. (1968) · Clinica Chimica Acta · doi:10.1016/0009-8981(68)90041-7 · Cited by 1,133
ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogensis produced by Penicillium citrinum.
Endo, A., KURODA, M., & Tsujita, Y. (1976) · The Journal of Antibiotics · doi:10.7164/antibiotics.29.1346 · Cited by 954
Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase
Brown, M. S., Faust, J. R., Goldstein, J. L., Kaneko, I., & Endo, A. (1978) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38120-6 · Cited by 556

Show all 41 references

Research works printed but not linked: 1

Miettinen, 1974, Eur J Clin Invest, 4, 365

Sorted by citations

Items 101–200 of 262

Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin
Grimbert, S., Pessayre, D., Degott, C., & Benhamou, J. (1994) · Digestive Diseases and Sciences · doi:10.1007/bf02088142 · Cited by 41
Brain and optic system pathology in hypocholesterolemic dogs treated with a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Berry, P. H., MacDonald, J. S., ALBERTS, A. W., Molon-Noblot, S., Chen, J. S., Lo, C. Y., Greenspan, M. D., Allen, H., Durand-Cavagna, G., & Jensen, R. (1988) · PubMed Central · Cited by 41
Management of Primary Mixed Hyperlipidemia With Lovastatin
Vega, G. L. (1990) · Archives of Internal Medicine · doi:10.1001/archinte.150.6.1313 · Cited by 40
Off‐target effects of statins: molecular mechanisms, side effects and the emerging role of kinases
Lagunas‐Rangel, F. A., Liepinsh, E., Fredriksson, R., Alsehli, A. M., Williams, M. J., Dambrova, M., Jönsson, J., & Schiöth, H. B. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17309 · Cited by 42
Treatment of homozygous patients with familial hypercholesterolemia by double-filtration plasmapheresis
Mabuchi, H., Michishita, I., Sakai, T., Sakai, Y., Watanabe, A., WAKASUGI, T., & Takeda, R. (1986) · Atherosclerosis · doi:10.1016/0021-9150(86)90073-0 · Cited by 38
Self-citation
Biochemical aspect of HMG CoA reductase inhibitors
Endo, A., & Hasumi, K. (1989) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(89)90063-0 · Cited by 38
Determination of pravastatin in human plasma by high-performance liquid chromatography with ultraviolet detection
Otter, K., & Mignat, C. (1998) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(97)00625-7 · Cited by 37
Influences of lovastatin administration on the respiratory burst of leukocytes and the phosphorylation potential of mitochondria in guinea pigs
Diebold, B. A., Bhagavan, N. V., & Guillory, R. J. (1994) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(94)90123-6 · Cited by 37
Increases in Creatine Kinase After Exercise in Patients Treated With HMG Co-A Reductase Inhibitors
Thompson, P. D., Nugent, A. M., & Herbert, P. N. (1990) · JAMA · doi:10.1001/jama.1990.03450230024013 · Cited by 37
Effects of exercise and lovastatin on serum creatine kinase activity
Thompson, P. D., Gadaleta, P. A., Yurgalevitch, S. M., Cullinane, E. M., & Herbert, P. N. (1991) · Metabolism · doi:10.1016/0026-0495(91)90039-y · Cited by 37
Hyperlipoproteinemia: Metabolic basis and rationale for therapy
Grundy, S. M. (1984) · The American Journal of Cardiology · doi:10.1016/0002-9149(84)90852-x · Cited by 37
5 alpha-Cholest-8(14)-en-3 beta-ol-15-one, a potent inhibitor of sterol biosynthesis, lowers serum cholesterol and alters distributions of cholesterol in lipoproteins in baboons.
Schroepfer, G. J., Parish, E. J., Kisić, A., Jackson, E., Farley, C. M., & Mott, G. E. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.9.3042 · Cited by 37
Probucol with Colestipol in the Treatment of Hypercholesterolemia
Dujovne, C. A., KREHBIEL, P., DECOURSEY, S., JACKSON, B., CHERNOFF, S. B., PITTERMAN, A., & MOSHE, G. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-100-4-477 · Cited by 37
Effects of Recombinant Interferon-α 2 Treatment upon Lipid Concentrations and Lipoprotein Composition
Massaro, E. R., Borden, E. C., Hawkins, M., Wiebe, D. A., & Shrago, E. S. (1986) · Journal of Interferon Research · doi:10.1089/jir.1986.6.655 · Cited by 36
The influence of mevinolin on the adrenal cortical response to corticotropin in heterozygous familial hypercholesterolemia.
Illingworth, D. R., & Corbin, D. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.18.6291 · Cited by 36
Lowering Plasma Cholesterol by Raising LDL Receptors — Revisited
Young, S. G., & Fong, L. G. (2012) · New England Journal of Medicine · doi:10.1056/nejme1202168 · Cited by 37
Regulation of rat liver hydroxymethylglutaryl coenzyme A reductase by a new class of noncompetitive inhibitors. Effects of dichloroacetate and related carboxylic acids on enzyme activity.
Stacpoole, P. W., Harwood, H. J., & Varnado, C. E. (1983) · Journal of Clinical Investigation · doi:10.1172/jci111116 · Cited by 34
3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitors
Illingworth, D. R., & Schmidt, E. B. (1994) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-78426-2_11 · Cited by 34
A Review of Progress on Targeting LDL Receptor-Dependent and -Independent Pathways for the Treatment of Hypercholesterolemia, a Major Risk Factor of ASCVD
Srivastava, R. A. K. (2023) · Cells · doi:10.3390/cells12121648 · Cited by 40
Treatment of Hyperlipidemia in the Nephrotic Syndrome: The Effects of Pravastatin Therapy
Spitalewitz, S., Porush, J. G., Cattran, D. C., & Wright, N. (1993) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)70180-4 · Cited by 33
Living-donor liver transplantation for homozygous familial hypercholesterolemia from a donor with heterozygous hypercholesterolemia.
Shirahata, Y., Ohkohchi, N., Kawagishi, N., Syouji, M., Tsukamoto, S., Sekiguchi, S., Koyamada, N., Oikawa, S., & Satomi, S. (2003) · PubMed · doi:10.1007/s00147-002-0534-6 · Cited by 32
Clinical Implications of New Drugs for Lowering Plasma Cholesterol Concentrations
Illingworth, D. R. (1991) · Drugs · doi:10.2165/00003495-199141020-00001 · Cited by 32
A New and Efficient Chemoenzymatic Route to Both Enantiomers of 4-Hydroxycyclohex-2-en-1-one
DEMİR, A. S., & Şeşenoğlu, Ö. (2002) · Organic Letters · doi:10.1021/ol025847+ · Cited by 31
Living-donor liver transplantation for homozygous familial hypercholesterolemia from a donor with heterozygous hypercholesterolemia
Shirahata, Y., Ohkohchi, N., Kawagishi, N., Syouji, M., Tsukamoto, S., Sekiguchi, S., Koyamada, N., Oikawa, S., & Satomi, S. (2003) · Transplant International · doi:10.1111/j.1432-2277.2003.tb00299.x · Cited by 31
Determination of pravastatin sodium and its isomeric metabolite in human urine by HPLC with UV detection
Whigan, D. B., Ivashkiv, E., & Cohen, A. I. (1989) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/0731-7085(89)80013-5 · Cited by 31
Comparison of lovastatin and probucol in treatment of familial and non-familial hypercholesterolemia: different effects on lipoprotein profiles
Helve, E., & Tikkanen, M. J. (1988) · Atherosclerosis · doi:10.1016/0021-9150(88)90080-9 · Cited by 31
Optimal management of hyperlipidemia in primary prevention of cardiovascular disease
Raza, J. A., Babb, J. D., & Movahed, A. (2004) · International Journal of Cardiology · doi:10.1016/j.ijcard.2003.07.039 · Cited by 30
Statins: A Potential Therapeutic Addition to Treatment for Aneurysmal Subarachnoid Hemorrhage?
Sabri, M., & Macdonald, R. L. (2010) · World Neurosurgery · doi:10.1016/j.wneu.2010.03.032 · Cited by 29
Overview of the LDL receptor: relevance to cholesterol metabolism and future approaches for the treatment of coronary heart disease
Millar, J. S., & Lagor, W. R. (2009) · Journal of Receptor Ligand and Channel Research · doi:10.2147/jrlcr.s6033 · Cited by 30
Inhibition of cholesterol synthesis by mevinolin stimulates low density lipoprotein receptor activity in human monocyte-derived macrophages
Traber, M. G., & Kayden, H. J. (1984) · Atherosclerosis · doi:10.1016/0021-9150(84)90152-7 · Cited by 28
National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2015) · Cited by 27
Pharmacological approaches to the modulation of plasma cholesterol
Shepherd, J., & Packard, C. J. (1988) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(88)90104-6 · Cited by 26
Regulation of Low Density Lipoprotein Receptor Function in a Human Hepatoma Cell Line
Leichtner, A. M., Krieger, M., & Schwartz, A. L. (1984) · Hepatology · doi:10.1002/hep.1840040518 · Cited by 26
Long-term effects of ileal bypass on lipoproteins in patients with familial hypercholesterolemia.
Koivisto, P., & Miettinen, T. A. (1984) · Circulation · doi:10.1161/01.cir.70.2.290 · Cited by 25
Guar gum and gemfibrozil — an effective combination in the treatment of hypercholesterolaemia
Tuomilehto, J. O., Silvasti, M., Manninen, V., Uusitupa, M. I. J., & Aro, A. (1989) · Atherosclerosis · doi:10.1016/0021-9150(89)90195-0 · Cited by 24
Hypolipidemic effect and mechanism of ketoconazole without and with cholestyramine in familial hypercholesterolemia
Gylling, H., Vanhanen, H. T., & Miettinen, T. A. (1991) · Metabolism · doi:10.1016/0026-0495(91)90189-4 · Cited by 23
Potential Use of γ-Secretase Modulators in the Treatment of Alzheimer Disease
Wagner, S. L., Tanzi, R. E., Mobley, W. C., & Galasko, D. R. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.540 · Cited by 22
What is the optimal medical management of ischemic heart failure?
Cleland, J. G. F., Alamgir, F. M., Nikitin, N. P., Clark, A. L., & Norell, M. S. (2001) · Progress in Cardiovascular Diseases · doi:10.1053/pcad.2001.20670 · Cited by 22
Statin-related Muscle Toxicity: An Evidence-based Review
Jeeyavudeen, M. S., Pappachan, J. M., & Arunagirinathan, G. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.2.89 · Cited by 21
Effects of MK‐733 on plasma lipid and lipoprotein levels in subjects with hypercholesterolaemia
Simons, L. A., Nestel, P. J., Calvert, G. D., & Jennings, G. (1987) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1987.tb133261.x · Cited by 21
Increased cholesterol biosynthesis in leukemic cells from patients with hairy cell leukemia
Yachnin, S., Golomb, H., West, E., & Saffold, C. W. (1983) · Blood · doi:10.1182/blood.v61.1.50.50 · Cited by 21
Flavonoid-statin interactions causing myopathy and the possible significance of OATP transport, CYP450 metabolism and mevalonate synthesis
Zechner, J., Britza, S. M., Farrington, R., Byard, R. W., & Musgrave, I. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119975 · Cited by 21
The Lausanne Institutional Biobank: A new resource to catalyse research in personalised medicine and pharmaceutical sciences
Mooser, V., & Currat, C. (2014) · Swiss Medical Weekly · doi:10.4414/smw.2014.14033 · Cited by 21
PLASMA MEVALONATE RESPONSE IN LOVASTATIN-RELATED MYOPATHY
Maher, V. M. G., Pappu, A. S., Illingworth, D. R., & Thompson, G. R. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91109-4 · Cited by 18
Comparison of simvastatin and cholestyramine in the treatment of primary hypercholesterolemia
O’Brien, R. C., Cooper, M. E., Jerums, G., Simons, L. A., Clifton, P. M., Nestel, P. J., Jennings, G., & SULLIVAN, D. R. (1990) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1990.tb125308.x · Cited by 18
Drugs inhibiting HMG-CoA reductase
Endo, A. (1985) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(85)90025-7 · Cited by 17
Improved synthesis of racemic and optically active 4-hydroxycyclohex-2-en-1-one
Marchand, A. P., Xing, D., Wang, Y., & Bott, S. G. (1995) · Tetrahedron Asymmetry · doi:10.1016/0957-4166(95)00360-2 · Cited by 17
The Effect of Pravastatin on Plasma Lipoprotein and Apolipoprotein Levels in Primary Hypercholesterolemia
Rubenfire, M. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.1991.00400110086018 · Cited by 17
Synthesis and biological activity of the hexalin moiety of compactin (ML-236B)
Heathcock, C. H., Taschner, M. J., Rosen, T., Thomas, J. A., Hadley, C. R., & Popják, G. J. (1982) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)85703-2 · Cited by 17
Normalization of low-density lipoprotein levels and disappearance of xanthomas during pregnancy in a woman with heterozygous familial hypercholesterolemia
Mabuchi, H., Sakai, Y., Watanabe, A., Haba, T., Koizumi, J., & Takeda, R. (1985) · Metabolism · doi:10.1016/0026-0495(85)90219-7 · Cited by 17
Self-citation
Effect of simvastatin on receptor mediated metabolism of low density lipoprotein in guinea pigs
Matsunaga, A., Sasaki, J., Takada, Y., Hidaka, K., & Arakawa, K. (1991) · Atherosclerosis · doi:10.1016/0021-9150(91)90241-t · Cited by 17
HDL as a Treatment Target: Should We Abandon This Idea?
Bègue, F., Apalama, M. L., Lambert, G. C., & Meilhac, O. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01176-1 · Cited by 16
Effects of CS-514 (eptastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipid and apolipoprotein levels in heterozygous familial hypercholesterolemic patients treated by low density lipoprotein (LDL) -apheresis
Mabuchi, H., Fujita, H., Michishita, I., TAKEDA, M., Kajinami, K., Koizumi, J., Takeda, R., Takegoshi, T., WAKASUGI, T., Ueda, K., et al. (1988) · Atherosclerosis · doi:10.1016/0021-9150(88)90079-2 · Cited by 16
Self-citation
Hypercholesterolemia and atherosclerosis: Present and future therapy including LDL‐apheresis
Kottke, B. A., Pineda, A. A., Case, M. T., Orsuzar, A. M., & Brzys, K. A. (1988) · Journal of Clinical Apheresis · doi:10.1002/jca.2920040108 · Cited by 15
Efficacy of Colestimide Coadministered With Atorvastatin in Japanese Patients With Heterozygous Familial Hypercholesterolemia (FH)
Kawashiri, M., Higashikata, T., Nohara, A., Kobayashi, J., Inazu, A., Koizumi, J., & Mabuchi, H. (2005) · Circulation Journal · doi:10.1253/circj.69.515 · Cited by 15
Self-citation
Plasma Lipoproteins, Apolipoproteins, and Proteins Concerned with Lipid Metabolism
Calvert, G. D., & Abbey, M. (1985) · Advances in clinical chemistry · doi:10.1016/s0065-2423(08)60274-7 · Cited by 16
Pharmacological treatment of lipid disorders in diabetes mellitus
Lopes-Virella, M. F., & Colwell, J. A. (1987) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610030305 · Cited by 15
The Mechanism of Action of Lipid-Lowering Drugs
LaRosa, J. C. (1982) · Angiology · doi:10.1177/000331978203300902 · Cited by 15
Long‐term effects of simvastatin in familial dysbetalipoproteinaemia
Stuyt, P. M. J., Mol, M. J. T. M., & Stalenhoef, A. F. H. (1991) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1991.tb00423.x · Cited by 14
Is Calcitriol Life-Protective for Patients with Chronic Kidney Disease?
Thadhani, R. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009050494 · Cited by 14
Treatment B) Drug Therapy
Teramoto, T., Sasaki, J., Ishibashi, S., Birou, S., Daida, H., Dohi, S., Egusa, G., Hiro, T., Hirobe, K., Iida, M., et al. (2013) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.19166 · Cited by 13
CHOLESTEROL AND NEURONAL SUSCEPTIBILITY TO BETA-AMYLOID TOXICITY.
Nicholson, A. M., & Ferreira, A. (2010) · PubMed · Cited by 13
Combined treatment with cholestyramine and nicotinic acid in heterozygous familial hypercholesterolaemia: effects on biliary lipid composition
Angelin, B., Eriksson, M., & Einarsson, K. (1986) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1986.tb01014.x · Cited by 13
Antioxidant Activity of Ubiquinone-3 in Human Low Density Lipoprotein
Merati, G., Pasquali, P., Vergani, C., & Landi, L. (1992) · Free Radical Research Communications · doi:10.3109/10715769209049154 · Cited by 13
Specific Nonsterol Inhibitors of HMG-CoA Reductase
Endo, A. (1985) · Elsevier eBooks · doi:10.1016/b978-0-12-564430-3.50006-2 · Cited by 13
PCSK9 inhibitors for treating familial hypercholesterolaemia
Mabuchi, H., & Nohara, A. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.205 · Cited by 12
Self-citation
Pharmacotherapy in familial hypercholesterolemia - Current state and emerging paradigms
Kallapur, A. S., & Sallam, T. (2021) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.12.011 · Cited by 14
The diagnosis and management of hyperlipidemia
Gotto, A. M., Jones, P. H., & Scott, L. W. (1986) · Disease-a-Month · doi:10.1016/s0011-5029(86)80011-6 · Cited by 12
A new and efficient chemoenzymatic route to both enantiomers of α′-acetoxy-α-methyl and γ-hydroxy-α-methyl cyclic enones
DEMİR, A. S., Fındık, H., & Köse, E. (2004) · Tetrahedron Asymmetry · doi:10.1016/j.tetasy.2003.12.006 · Cited by 12
Window panes of eternity. Health, disease, and inherited risk.
Scriver, C. R. (1982) · PubMed Central · Cited by 12
A diastereoselective synthesis of 4(RS), 6(SR)-mercaptomethylmevalonolactone, a key intermediate in the preparation of a new class of inhibitors of HMG-CoA reductase
FERRES, H., Hatton, I. K., JENNINGS, L. J., TYRRELL, A. W. R., & Williams, D. (1983) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)94530-1 · Cited by 12
Hyperlipidemia
Glatter, T. R. (1984) · Postgraduate Medicine · doi:10.1080/00325481.1984.11698776 · Cited by 11
3-Hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors: A New Class of Cholesterol-Lowering Agents
GORDON, D. J., & Rifkind, B. M. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-5-759 · Cited by 11
Plasma Cortisol and Testosterone in Hypercholesterolaemia Treated with Clofibrate and Lovastatin
Mastroberardino, G., da Costa, C. A. S., Ms, G., Vitaliano, E., Rossi, F., Catalano, A., Barletta, R., & Guarini, G. (1989) · Journal of International Medical Research · doi:10.1177/030006058901700413 · Cited by 11
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000, vol. 27.
Reynolds, L., & Em, T. (2006) · UCL Discovery (University College London) · Cited by 10
Drug and alternative therapies for hyperlipidemia
Stein, E. A. (1994) · Atherosclerosis · doi:10.1016/0021-9150(94)90156-2 · Cited by 10
Pravastatin Sodium, a New Hmg-CoA Reductase Inhibitor
Raasch, R. H. (1991) · DICP · doi:10.1177/106002809102500410 · Cited by 10
Regulation of HMG-CoA Reductase and the Biosynthesis of Nonsteroid Prenyl Derivatives
ANINI, S. R., ROGERS, D. H., & RUD, H. (1985) · Elsevier eBooks · doi:10.1016/b978-0-12-564430-3.50009-8 · Cited by 10
What is the optimal medical management of ischaemic heart failure?
Cleland, J. G. F., John, J., Dhawan, J., & Clark, A. L. (2001) · British Medical Bulletin · doi:10.1093/bmb/59.1.135 · Cited by 9
Inhibition of Cholesterol Synthesis
Kritchevsky, D. (1987) · Journal of Nutrition · doi:10.1093/jn/117.7.1330 · Cited by 9
HMG-Coa Reductase Inhibitors
Endo, A. (1985) · Springer eBooks · doi:10.1007/978-1-4613-2459-1_23 · Cited by 9
Hypercholesterolemia Persisting After Distal Ileal Bypass: Response to Mevinolin
Illingworth, D. R., & CONNOR, W. E. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-100-6-850 · Cited by 9
Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in various forms of dyslipidemia
Grundy, S. M., Vega, G. L., & Garg, A. (1990) · The American Journal of Cardiology · doi:10.1016/0002-9149(90)90438-7 · Cited by 9
13 Low-density lipoprotein receptors
Kovanen, P. T. (1983) · Clinics in Endocrinology and Metabolism · doi:10.1016/s0300-595x(83)80038-3 · Cited by 9
New opportunities in the management and treatment of refractory hypercholesterolemia using in vivo CRISPR-mediated genome/base editing
Srivastava, R. A. K. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.08.010 · Cited by 8
Statins: Definitive Translational Research
Grundy, S. M. (2014) · Molecular Medicine · doi:10.2119/molmed.2014.00194 · Cited by 8
Clinical efficacy and safety of cerivastatin in the treatment of heterozygous familial hypercholesterolemia
Mabuchi, H., Koizumi, J., & KAJINAMI, K. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00438-x · Cited by 8
Self-citation
The Briard Problem
Riis, R. C., & Aguirre, G. K. (1983) · Cited by 8
PCSK9: the Critical Role of Familial Hypercholesterolemia from Discovery to Benefit for all
Stein, E. A. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6690-1 · Cited by 7
8 Dietary therapy of hyperlipidaemia
Grundy, S. M. (1987) · Baillière s Clinical Endocrinology and Metabolism · doi:10.1016/s0950-351x(87)80028-9 · Cited by 7
Cardiovascular risk factors and mortality
Tonkin, A. M. (1988) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1988.tb104504.x · Cited by 7
Cholesterol and mevalonic acid are independent requirements for the in vitro proliferation of human bone marrow granulocyte progenitor cells: studies using ML-236B
Hoffman, P. C., Richman, C., Larson, R. A., & Yachnin, S. (1983) · Blood · doi:10.1182/blood.v61.4.667.667 · Cited by 7
Regulation of Low Density Lipoprotein Receptor Function in a Human Hepatoma Cell Line
Leichtner, A. M., Krieger, M., & Schwartz, A. L. (1984) · Hepatology · doi:10.1002/hep.1840040638 · Cited by 7
Discovery and Development of Statins
Endo, A. (2017) · Natural Product Communications · doi:10.1177/1934578x1701200801 · Cited by 6
Chapter 17. Progress in Atherosclerosis Therapy: Hypolipidemic Agents
Prugh, J. D., & Rooney, C. S. (1983) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)60772-1 · Cited by 6
Activity of 3-hydroxy-3-methylglutaryl-coenzyme A reductase does not respond to ubiquinone uptake in cultured cells
Maltese, W. A., Aprille, J. R., & Green, R. A. (1987) · Biochemical Journal · doi:10.1042/bj2460441 · Cited by 6
The evolution of lipid-lowering drugs in the management of cardiovascular disease risk: From the first cardiovascular disease risk–reducing therapies to the novel challenging strategies
Henry, D., Baugé, E., Staels, B., & Lalloyer, F. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100086 · Cited by 5
Pathophysiology of human lipoprotein receptors: clinical consequences of a cellular defect.
Shepherd, J., & Packard, C. J. (1984) · Journal of Clinical Pathology · doi:10.1136/jcp.37.1.87 · Cited by 5
SCREENING FOR HYPERCHOLESTEROLAEMIA ON BLOOD-SPOTTED FILTERPAPER
Asami, T. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90219-2 · Cited by 5
Therapeutic use of HMG-CoA reductase inhibitors: current practice and future perspectives
Cattaneo, D., Baldelli, S., Merlini, S., Zenoni, S., Perico, N., & Remuzzi, G. (2004) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.14.11.1553 · Cited by 5

Authors: Mabuchi, H., Haba, T., Tatami, R., Miyamoto, S., Sakai, Y., Wakasugi, T., Watanabe, A., Koizumi, J., & Takeda, R.
Affiliations: Kanazawa University (JP)
ORCID: Miyamoto, Susumu
Sakai, Yasuyuki
Watanabe, Akira
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1981-08-27
Volume: 305
Issue: 9
Pages: 478-482
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm198108273050902
OpenAlex: W2051105453
Cited by: 262
References: 41
Citations by year: 2025: 2 · 2024: 6 · 2023: 8 · 2022: 2 · 2021: 6 · 2020: 5 · 2019: 3 · 2018: 3 · 2017: 6 · 2016: 3 · 2015: 3 · 2014: 5 · 2013: 2 · 2012: 2
FWCI: 25.89
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
Keywords: ML-236B, statins, familial hypercholesterolemia, serum cholesterol, serum triglycerides, lipoproteins, LDL cholesterol, intermediate density lipoprotein, ubiquinone-10
MeSH terms: Adult, Aged, Cholesterol, Female, Heterozygote, Humans, Hyperlipoproteinemia Type II, Lipoproteins, Lipoproteins, HDL, Lipoproteins, LDL, Lipoproteins, VLDL, Lovastatin, Male, Middle Aged, Naphthalenes, Triglycerides, Ubiquinone, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effects of an Inhibitor of 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase on Serum Lipoproteins and Ubiquinone-10 Levels in Patients with Familial Hypercholesterolemia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks